Berenberg Downgrades Novo Nordisk on Lilly's Oral Lead
Berenberg has downgraded Novo Nordisk, saying the oral Wegovy story is spent and Eli Lilly is claiming the pill market. Novo shares fell 2.08% to 46.19 DKK on the call.
Berenberg cut its rating on Novo Nordisk A/S (OMX: NVO), arguing that upside from the oral Wegovy pill has already been priced in and that Eli Lilly is taking the oral obesity market, with Novo shares trading at 46.19 DKK, down 2.08%, at 17:36 GMT on 12 August 2026.
Berenberg has cut its rating on Novo Nordisk A/S (OMX: NVO), and the reasoning is unusually blunt for a sell-side downgrade: the oral obesity market, the one segment where Novo was supposed to have first-mover advantage, is being taken by Eli Lilly and Co (NYSE: LLY). The upside from the Wegovy pill, in the broker's view, has already played out in the share price, leaving Novo's valuation multiple sitting at the European pharmaceutical average rather than at the premium a franchise-defining growth story would command.
The market took the point. Novo shares were trading at 46.19 DKK as of 17:36 GMT on 12 August 2026, down 2.08% from the previous close of 47.17 DKK, and near the lower end of a session range of 45.56 DKK to 46.30 DKK. Lilly, by contrast, was essentially flat at $1,214.93, down 0.01% against a prior close of $1,215.02, though the stock swung across a wide intraday band of $1,191.08 to $1,226.50.
Why the pill was supposed to be Novo's moat
Injectable GLP-1 drugs built the obesity market, but the consensus for years has been that the mass market is oral. A tablet is cheaper to make, easier to distribute, easier for a primary-care physician to prescribe and vastly easier for a patient to start. Whoever led in pills was expected to convert the several hundred million people who will never accept a weekly injection.
Novo's claim on that future rested on an oral version of Wegovy — the same semaglutide molecule that made the company Europe's most valuable listed business, reformulated as a swallowable dose. Berenberg's argument, as reported by GuruFocus, is that the market has already paid for that optionality. Once the incremental news flow is priced, an oral launch stops being a catalyst and becomes an operational grind against a competitor with its own pill.
A multiple that no longer says "growth stock"
The valuation observation is the part investors should sit with longest. A company trading at the European pharma sector average is being priced like a European pharma company — durable, cash-generative, patent-exposed — and not like the compounder that the GLP-1 boom made it look like. That is a large reframing of the equity story, because it changes who owns the shares. Growth funds buy narrative acceleration; value and income funds buy average multiples with above-average cash flow. The transition between those two shareholder bases is rarely smooth, and it is usually what produces the kind of grinding derating that shows up as a share price near the bottom of its daily range on downgrade days.
It also removes the cushion that a premium multiple provides. When a stock trades above its sector, disappointing news compresses the premium first. When it trades at the sector average, disappointing news has to come out of the earnings estimate itself.
Lilly's flat tape says something too
Lilly barely moved on a day when its principal competitor was downgraded partly in its favour — a reminder that the market has been positioning for Lilly's oral leadership for some time, and that incremental confirmation no longer moves a stock trading above $1,200. What is notable is the volatility around the flat close: the intraday spread between the session low of $1,191.08 and high of $1,226.50 works out to roughly $35, an illustrative gap of about 2.9% of the prior close, on a day when the broad market was quiet. The S&P 500 tracker (SPY) was up 0.30% at $772.85, the Dow proxy (DIA) up 0.06% at $537.58, and the Nasdaq 100 fund (QQQ) up 0.92% at $725.09. Obesity-complex stocks are trading on their own news cycle, not the index's.
What the downgrade does not settle
Several things remain open, and investors should be careful not to read more into a single broker call than it contains.
- Volume versus value. Oral leadership measured in prescriptions is not the same as oral leadership measured in profit. Pills invite payer pressure and price competition faster than injectables did.
- Manufacturing scale. Both companies have spent heavily on capacity. Whoever can actually supply a mass-market oral drug at scale may matter more than whose data package is marginally better.
- Novo's injectable base. The downgrade is about the pill opportunity, not a claim that the existing franchise is impaired.
- The average-multiple floor. Sector-average valuation can be a warning or a support level, depending on whether earnings estimates hold.
What to watch from here
The practical checklist for the next few quarters is short. First, whether other brokers follow Berenberg — a lone downgrade on valuation grounds is noise, a cluster is a regime change in how the sell side frames Novo. Second, whether Novo's reported oral prescription trends validate or refute the premise that Lilly is taking the segment; share data will settle this argument faster than any note. Third, whether Novo's multiple stays at the European average or slips below it, which would signal that investors have moved from "fairly valued" to "structurally challenged."
For holders, the message embedded in the call is that the easy phase of the obesity trade is over on the Novo side. The stock no longer carries a premium to lose, but it also no longer carries an obvious catalyst to gain one back. That is a very different investment from the one that dominated European equity performance during the injectable era, and it deserves to be underwritten differently — on cash flow, pipeline breadth and pricing durability rather than on the assumption that the pill market was always going to be Novo's to win.
Key facts
- Novo Nordisk (OMX: NVO): 46.19 DKK, -2.08%, as of 17:36 GMT 12 Aug 2026
- Eli Lilly (NYSE: LLY): $1,214.93, -0.01%, as of 17:36 GMT 12 Aug 2026
- Broker action: Berenberg cut its rating on Novo Nordisk
- Valuation: Novo's multiple now at the European pharma average
Frequently asked questions
What did Berenberg actually do to Novo Nordisk?
Berenberg cut its rating on Novo Nordisk A/S. The broker's stated reasoning was that Eli Lilly is taking the oral obesity drug market and that the upside from Novo's Wegovy pill had already played out in the share price, leaving the company's valuation multiple at the European pharmaceutical sector average rather than at a growth premium.
How did Novo Nordisk shares react?
Novo Nordisk was trading at 46.19 DKK as of 17:36 GMT on 12 August 2026, down 2.08% from the previous close of 47.17 DKK. The shares changed hands within a session range of 45.56 DKK to 46.30 DKK, closer to the day's low than its high.
Did Eli Lilly stock rise on the news?
No. Eli Lilly was effectively unchanged at $1,214.93, down 0.01% against a prior close of $1,215.02. The stock was volatile intraday, however, ranging from $1,191.08 to $1,226.50, suggesting the market had already priced in expectations about Lilly's position in oral obesity treatment.
Why does the oral GLP-1 market matter so much?
A pill is cheaper to manufacture and distribute, simpler for physicians to prescribe and far easier for patients to begin than a weekly injection. That makes oral formulations the likely route to mass-market adoption of obesity treatment, which is why leadership in pills is treated as the decisive competitive question.
What does trading at the European pharma average imply?
It means investors are valuing Novo Nordisk like a typical large European drugmaker rather than a high-growth compounder. That removes the premium cushion that absorbs bad news, shifts the likely shareholder base from growth funds toward value buyers, and means future disappointments hit earnings estimates directly.
What should investors watch next?
Three things: whether other brokers follow Berenberg with their own downgrades, whether Novo's reported oral prescription share confirms or contradicts the claim that Lilly is winning the segment, and whether Novo's valuation multiple holds at the European sector average or slips below it.
Sources
Photo: Castorly Stock · Pexels Licence — source
